N4 Pharma Competitors

N4 Pharma (LON:N4P) and AstraZeneca (LON:AZN) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, profitability, analyst recommendations and valuation.

Profitability

This table compares N4 Pharma and AstraZeneca's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares N4 Pharma and AstraZeneca's gross revenue, earnings per share and valuation.

N4 Pharma is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations for N4 Pharma and AstraZeneca, as provided by MarketBeat.com.

AstraZeneca has a consensus target price of GBX 8,757.06, indicating a potential upside of 14.59%. Given AstraZeneca's higher probable upside, analysts plainly believe AstraZeneca is more favorable than N4 Pharma.

Summary

AstraZeneca beats N4 Pharma on 5 of the 6 factors compared between the two stocks.

GlaxoSmithKline (LON:GSK) and N4 Pharma (LON:N4P) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, valuation, analyst recommendations and institutional ownership.

Profitability

This table compares GlaxoSmithKline and N4 Pharma's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares GlaxoSmithKline and N4 Pharma's revenue, earnings per share (EPS) and valuation.

N4 Pharma is trading at a lower price-to-earnings ratio than GlaxoSmithKline, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and price targets for GlaxoSmithKline and N4 Pharma, as reported by MarketBeat.

GlaxoSmithKline presently has a consensus price target of GBX 1,533.80, indicating a potential upside of 14.03%. Given GlaxoSmithKline's higher possible upside, analysts clearly believe GlaxoSmithKline is more favorable than N4 Pharma.

Summary

GlaxoSmithKline beats N4 Pharma on 5 of the 6 factors compared between the two stocks.

Dechra Pharmaceuticals (LON:DPH) and N4 Pharma (LON:N4P) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, valuation, analyst recommendations and institutional ownership.

Profitability

This table compares Dechra Pharmaceuticals and N4 Pharma's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Dechra Pharmaceuticals and N4 Pharma's revenue, earnings per share (EPS) and valuation.

N4 Pharma is trading at a lower price-to-earnings ratio than Dechra Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and price targets for Dechra Pharmaceuticals and N4 Pharma, as reported by MarketBeat.

Dechra Pharmaceuticals presently has a consensus price target of GBX 3,350, indicating a potential downside of 14.32%. Given Dechra Pharmaceuticals' higher possible upside, analysts clearly believe Dechra Pharmaceuticals is more favorable than N4 Pharma.

Summary

Dechra Pharmaceuticals beats N4 Pharma on 5 of the 6 factors compared between the two stocks.

Hutchison China MediTech (LON:HCM) and N4 Pharma (LON:N4P) are both companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability.

Profitability

This table compares Hutchison China MediTech and N4 Pharma's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Hutchison China MediTech and N4 Pharma's top-line revenue, earnings per share (EPS) and valuation.

Hutchison China MediTech is trading at a lower price-to-earnings ratio than N4 Pharma, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and recommmendations for Hutchison China MediTech and N4 Pharma, as reported by MarketBeat.com.

Summary

N4 Pharma beats Hutchison China MediTech on 3 of the 4 factors compared between the two stocks.

Vectura Group (LON:VEC) and N4 Pharma (LON:N4P) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability.

Profitability

This table compares Vectura Group and N4 Pharma's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Vectura Group and N4 Pharma's top-line revenue, earnings per share (EPS) and valuation.

N4 Pharma is trading at a lower price-to-earnings ratio than Vectura Group, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and recommmendations for Vectura Group and N4 Pharma, as reported by MarketBeat.com.

Vectura Group currently has a consensus price target of GBX 134, indicating a potential upside of 18.21%. Given Vectura Group's higher possible upside, equities research analysts plainly believe Vectura Group is more favorable than N4 Pharma.

Summary

Vectura Group beats N4 Pharma on 5 of the 6 factors compared between the two stocks.

Beximco Pharmaceuticals (LON:BXP) and N4 Pharma (LON:N4P) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability.

Analyst Ratings

This is a summary of current ratings and recommmendations for Beximco Pharmaceuticals and N4 Pharma, as reported by MarketBeat.com.

Profitability

This table compares Beximco Pharmaceuticals and N4 Pharma's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Beximco Pharmaceuticals and N4 Pharma's top-line revenue, earnings per share (EPS) and valuation.

Summary

N4 Pharma beats Beximco Pharmaceuticals on 1 of the 1 factors compared between the two stocks.